NEUROENDOCRINE TUMOURS: 2016 UPDATE
Abstract:
The field of neuroendocrine tumours (NETs) is complex and dynamic, recently
becoming a hot spot on publications area. We aim at presenting new frames of NETs approach.
This is a narrative review using an English literature PubMed research (publications only from
2016). The main stream of NETs management includes somatostatin analogs with good effects on
carcinoid syndrome and proliferation rate; peptide receptor radionuclide therapy (NETTER-1
study). New products as peripheral tryptophan hydroxylase oral inhibitors (TELESTAR study)
are opening promising doors. RADIANT-4 results were recently published; everolimus becoming
an essential line therapy especially for pancreas. Surgical approach of NETs remains important.
The decision of surgery is based on tumours’ size and site, functional pattern, local and distant
invasion. The indications of performing surgery for metastasis are mostly unchanged and this
decision must be taken under multi-disciplinary considerations. Despite recent progress, there
are still many missing pieces of the puzzle represented by NETs domain.
full text article in English (.EN) |